FDA Revamps Safety Testing for new Type 2 Diabetes Drugs

In a draft guidance issued Monday, the US Food and Drug administration (FDA) proposed a new, broader approach to conducting safety evaluations for new drugs to treat type 2 diabetes that looks beyond assessing cardiovascular (CV) risk.